Eliem Therapeutics Announces Additions to its Leadership Team
Written by Emily J. Thompson, Senior Investment Analyst
0mins
Source: Newsfilter
New Executive Appointments: Eliem Therapeutics has appointed Brett Kaplan, M.D. as Chief Operating Officer and Nishi Rampal, M.D. as Senior Vice President of Clinical Development to strengthen its management team following the acquisition of Tenet Medicines.
Focus on Autoimmune Diseases: The company aims to advance its lead asset, budoprutug, an anti-CD19 antibody targeting various autoimmune diseases, leveraging the extensive experience of the new executives in biotechnology and clinical development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
